Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of entrectinib versus crizotinib in ROS1-positive advanced or metastatic non-small cell lung cancer
CTR20211054Phase 3Active
- Sponsor
- Roche
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of entrectinib, crizotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Nov 2021; status: active.
02
Drugs
entrectinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20211054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211054.